PPARγ agonists: A new strategy for antithrombotic therapy

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2147-2148

  Smyth, Susan S ^a   Jennings, J L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CD40 LIGAND; GLIPIZIDE; GLUCOSE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; THROMBOMODULIN; TROGLITAZONE; ANTIDIABETIC AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTIGEN EXPRESSION; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; ARTICLE; DIABETIC ANGIOPATHY; DRUG POTENTIATION; HYPERGLYCEMIA;

DIABETIC ANGIOPATHIES; FIBRINOLYTIC AGENTS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PLATELET ACTIVATION; PPAR GAMMA; THIAZOLIDINEDIONES; THROMBOSIS;

EID: 28444469758     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01585.x     Document Type: Note

References (15)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
2. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
3. Kunhiraman BP, Jawa A, Fonseca VA. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am 2005; 34: 117-35.
4. Bodary P, Vargas FB, King SAD, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 3: 2149-53.
5. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-8.
6. Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, Romeo F, Mehta JL. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907-12.
7. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7.
8. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernandez-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schonbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolid-inediones. Circulation 2003; 107: 2664-9.
9. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-63.
10. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805-11.
11. Eligini S, Banfi C, Brambilla M, Camera M, Barbieri SS, Poma F, Tremoli E, Colli S. 15-deoxy-delta 12,14-prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 2002; 88: 524-32.
12. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Constantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
13. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davi G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
14. Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zanan A, Rodriguez OJ, Lev EI, Rauch U, Heflt G, Fallon JT, Crandall JP. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-12.
15. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: e25.